Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Abemaciclib - Eli Lilly and Company

Next Previous
Drug Profile

Abemaciclib - Eli Lilly and Company

Alternative Names: Abemaciclib mesylate; Bemaciclib; Bemaciclib mesylate; LY 2835219; Verzenio; Verzenios

Latest Information Update: 08 Apr 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company
  • Developer Boehringer Ingelheim; Dana-Farber Cancer Institute; Eli Lilly; Eli Lilly and Company; Jules Bordet Institute; M. D. Anderson Cancer Center; Memorial Sloan-Kettering Cancer Center; Merck Sharp & Dohme; National Cancer Institute (USA); UCLAs Jonsson Comprehensive Cancer Center; Washington University School of Medicine
  • Class Aminopyridines; Antineoplastics; Benzimidazoles; Fluorinated hydrocarbons; Piperazines; Pyrimidines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase III HER2 negative breast cancer; Liposarcoma; Prostate cancer
  • Phase II Adenocarcinoma; Brain cancer; Cholangiocarcinoma; Endometrial cancer; Ewing's sarcoma; Fallopian tube cancer; Glioblastoma; Mantle-cell lymphoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Solid tumours; Urogenital cancer
  • Phase I/II Head and neck cancer; Kaposi's sarcoma
  • Phase I Myelofibrosis
  • No development reported Cancer; Renal cell carcinoma

Most Recent Events

  • 08 Apr 2026 Efficacy and adverse event data from a phase III monarchE trial in Breast cancer presented at the 50th European Society for Medical Oncology Congress (ESMO-2025)
  • 21 Jan 2026 Eli Lilly and Company completes a phase I trial for Prostate cancer (Hormone refractory, Combination therapy, Metastatic diseases) in the US, Germany and Spain (NCT05999968)
  • 09 Dec 2025 Efficacy and pharmacodynamics data from a phase III EMBER-3 trial in Breast cancer presented at the 48th Annual San Antonio Breast Cancer Symposium (SABCS-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top